Advisor Net Financial, Inc Iovance Biotherapeutics, Inc. Transaction History

Advisor Net Financial, Inc

11 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2022 Apr 14, 2022	SELL	$12.38 - $19.1 $6,041 - $9,320	-488 Reduced 17.61%	2,283 $38,000
Q4 2021 Jan 19, 2022	SELL	$16.55 - $27.63 $3,508 - $5,857	-212 Reduced 7.11%	2,771 $53,000
Q3 2021 Oct 15, 2021	SELL	$20.35 - $26.63 $1,282 - $1,677	-63 Reduced 2.07%	2,983 $74,000
Q2 2021 Jul 06, 2021	SELL	$16.33 - $33.07 $49,626 - $100,499	-3,039 Reduced 49.94%	3,046 $79,000
Q1 2021 Apr 14, 2021	SELL	$28.67 - $52.59 $163,275 - $299,500	-5,695 Reduced 48.34%	6,085 $193,000
Q4 2020 Feb 04, 2021	BUY	$28.04 - $50.26 $12,337 - $22,114	440 Added 3.88%	11,780 $547,000
Q3 2020 Nov 06, 2020	BUY	$27.75 - $36.3 $12,487 - $16,334	450 Added 4.13%	11,340 $373,000
Q2 2020 Aug 26, 2020	BUY	$27.21 - $41.0 $190,742 - $287,410	7,010 Added 180.67%	10,890 $299,000
Q1 2020 May 14, 2020	BUY	$19.54 - $38.85 $75,815 - $150,738	3,880 New	3,880 $116,000
Q2 2019 Jul 15, 2019	SELL	$9.78 - $24.52 $7,823 - $19,616	-800 Closed	0 $0
Q1 2019 May 14, 2019	BUY	$8.41 - $11.26 $6,728 - $9,008	800 New	800 $8,000

314

241M

3.77M

1.7M

Ticker IOVA
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 157,800,992
Market Cap $1.36B
Description
Iovance Biotherapeutics, Inc., a clinical-stage biotechnology company, focuses on developing and commercializing cancer immunotherapy products to harness the power of a patient's immune system to eradicate cancer cells. It has six ongoing phase 2 clinical studies, including C-144-01, of its lead product candidate, lifileucel, for the treatment o...

Get notified when there are updates to the investment portfolio of Advisor Net Financial, Inc, based on Form 13F filings with the SEC.

Stay updated on Advisor Net Financial, Inc with notifications on news.